NeoTract ’ s UroLift system gains expanded insurance coverage

Teleflex (NYSE:TFX) subsidiary NeoTract said that two more health insurers have agreed to offer coverage for the company’s UroLift system or patients with an enlarged prostate. The Wayne, Penn.-based subsidiary of Teleflex said that major U.S. insurer Humana and the Motion Picture Industry Pension &Health Plans (MPI), administered by Anthem Blue Cross, have added UroLift to its covered treatment systems. UroLift is a minimally invasive in-office treatment designed to provide rapid relief and recovery from the symptoms of benign prostatic hyperplasia (BPH). “These coverage decisions are a major testament to the clinical benefits of the UroLift System for treating Benign Prostatic Hyperplasia (BPH), a common condition that significantly impacts the overall health of men with symptomatic BPH as well as the quality of life for those men and their partners,” said Teleflex interventional urology unit president Dave Amerson in a prepared statement. “We are pleased to see the continued acceptance of the UroLift System as a standard-of-care therapy for patients with symptomatic BPH. This coverage milestone will expand lasting and durable symptom relief to millions of men, allowing them to return to a healthier and better quality of life.” With these recent coverage decisions, a large majority of insured men in America now have access to the UroLift System procedure using their health insurance benefits, NeoTract said.     The ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blog Business/Financial News Featured Implants News Well Urology Anthem Blue Cross Blue Shield Humana NeoTract Teleflex Source Type: news

Related Links:

This study investigated the protein expression profile of STC1 in PCa and benign prostatic hyperplasia (BPH) samples and STC1 signalling during cell proliferation and cell death in vitro using cell lines. We found higher levels of STC1 in PCa when compared to BPH tissue and that STC1 inhibited forskolin stimulation of cAMP in PC-3 cells. A monoclonal antibody against STC1 was effective in reducing cell proliferation, in promoting cell cycle arrest, and in increasing apoptosis in the same cells. Since STC1 acts as a regulator of prostatic tissue signalling, we suggest that this protein is a novel candidate biomarker for p...
Source: Molecular and Cellular Endocrinology - Category: Endocrinology Source Type: research
ConclusionsIt was observed that extracts of S. hexaphylla inhibited both 5α -reductase type 2 and ARs. The results indicate that the use of S. hexaphylla extract in BPH is probably beneficial through 5α-reductase inhibition and α-adrenergic receptor blockade. In addition, apoptosis and autophagy were induced, and PCNA was downregulated after S. hexaphylla treatment. Therefore, it can be concluded that S. hexaphylla has a therapeutic effect on BPH.Graphical abstract
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Erectile Dysfunction;   Benign Prostatic Hyperplasia Interventions:   Drug: Tanzânia association;   Drug: Omnic Ocas Sponsor:   EMS Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: December 2019Source: European Urology Supplements, Volume 18, Issue 12Author(s): Sh.I. Giyasov, J.M. Yuldashev, M.Kh. Tukhtamishev, J.S. Saitkulo
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Purpose of review To summarize recent publications on the topic of laser in urology and explore new developments which may impact the future role of lasers in surgery. Recent findings Ho: Yttrium-aluminium garnet (YAG) laser with Moses technology allows less retropulsion during a lithotripsy, yet its efficacy needs to be tested in clinical trials. Data on the efficacy of this device for benign prostatic obstruction treatment is also pending. A new promising generation of laser systems – thulium-fiber (Tm-fiber) lasers – has been introduced. Tm-fiber has already been shown to be effective and well tolerated...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: BEST OF 2019: Edited by Johannes W. Vieweg and Shahrokh F. Shariat Source Type: research
Abstract Benign prostatic hyperplasia (BPH) is a common disease in older men, and there is evidence that obesity is a causal factor. It is currently unclear whether the hormone leptin, which is positively correlated to obesity, is involved in BPH. The aim of this study was to determine the effect of leptin on testosterone-induced BPH in mice and to explore possible underlying mechanisms. Testosterone (3 mg/kg) was injected into wild-type and leptin-deficient ob/ob male mice for 14 consecutive days, and prostate tissues were subjected to various analyses. Additionally, BPH epithelial-1 (BPH-1) cells were treated...
Source: Experimental Cell Research - Category: Cytology Authors: Tags: Exp Cell Res Source Type: research
Conclusions: Patients with benign adrenocortical tumors had higher odds of detected pancreatic IPMN, as well as thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia compared with patients with normal adrenal glands. These associations may have important implications for patient care and healthcare economics, regardless of whether they reflect incidental discoveries due to imaging detection or frequency bias, or a common risk for developing multiple neoplasia. PMID: 31781211 [PubMed]
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
To characterize the current landscape and future directions of academic benign prostatic hyperplasia (BPH) by using bibliometric analysis.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
This report in an immunocompetent 72-year-old man adds to the clinical spectrum of the five prior reported cases. A low threshold for prostatic biopsy led to a histological evaluation and subsequent microbiological confirmation of TB. This attests to the value of such an approach in arriving at the correct diagnosis and the institution of appropriate anti-tuberculous therapy even amongst immune-competent men. PMID: 31773934 [PubMed - in process]
Source: South African Journal of Surgery - Category: Surgery Tags: S Afr J Surg Source Type: research
We agree that preservation of ejaculation is viewed positively by patients and their partners. For many men, this factor alone helps them determine which of the myriad therapies for benign prostatic hyperplasia they ultimately select. Dr. Ulchaker is spot on with his observation that many benign prostatic hyperplasia therapies can result in ejaculatory dysfunction with varying rates among medical, minimally invasive technologies and surgery. However, we maintain that preservation of tissue near and around the verumontanum is key to ensuing ejaculatory preservation.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
More News: Benign Prostatic Hyperplasia | Blogging | Health Insurance | Insurance | Insurers | Pensions | Urology & Nephrology